TARS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TARS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Tarsus Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2025 was $-0.64. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-2.73.
Tarsus Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2025 was $-0.64. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 was $-2.73.
Tarsus Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2025 was $-0.64. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2025 was $-2.68.
During the past 3 years, the average EPS without NRIGrowth Rate was -69.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -11.90% per year.
During the past 7 years, Tarsus Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was -2.40% per year. The lowest was -69.60% per year. And the median was -17.85% per year.
The historical data trend for Tarsus Pharmaceuticals's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Earnings per Share (Diluted) | Get a 7-Day Free Trial | -4.32 | -0.67 | -2.52 | -4.62 | -3.07 |
Tarsus Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | |
Earnings per Share (Diluted) | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-1.01 | -0.88 | -0.61 | -0.60 | -0.64 |
For the Biotechnology subindustry, Tarsus Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's PE Ratio distribution charts can be found below:
* The bar in red indicates where Tarsus Pharmaceuticals's PE Ratio falls into.
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Tarsus Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2024 is calculated as
Diluted Earnings Per Share (A: Dec. 2024 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-115.554 | - | 0) | / | 37.605 | |
= | -3.07 |
Tarsus Pharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2025 is calculated as
Diluted Earnings Per Share (Q: Mar. 2025 ) | = | (Net Income | - | Preferred Dividends | / | Shares Outstanding (Diluted Average) |
= | (-25.12 | - | 0) | / | 39.345 | |
= | -0.64 |
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.73
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
Tarsus Pharmaceuticals (NAS:TARS) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Tarsus Pharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Bobak R. Azamian | director, 10 percent owner, officer: President and CEO | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Dianne C. Whitfield | officer: Chief Human Resources Officer | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Bryan Wahl | officer: General Counsel | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Seshadri Neervannan | officer: Chief Operating Officer | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Aziz Mottiwala | officer: Chief Commercial Officer | 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401 |
Jeffrey S Farrow | officer: See Remarks | TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Link William J Phd | director | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Jose M. Trevejo | officer: Chief Medical Officer | C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Andrew D. Goldberg | director | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Elizabeth Yeu Lin | director | 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630 |
Leonard M. Greenstein | officer: Chief Financial Officer | 24562 BELGREEN PLACE, LAKE FOREST CA 92630 |
Mark J. Holdbrook | officer: V.P., Clinical Affairs | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Scott W Morrison | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
Vivo Capital Fund Ix, L.p. | 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
Michael Ackermann | director, 10 percent owner | 202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540 |
From GuruFocus
By GuruFocus News • 02-28-2025
By GuruFocus News • 02-26-2025
By Marketwired • 03-12-2025
By GuruFocus News • 01-13-2025
By Marketwired • 03-06-2025
By GuruFocus News • 02-22-2025
By GuruFocus News • 04-22-2025
By GuruFocus News • 11-15-2024
By Marketwired • 03-13-2025
By GlobeNewswire • 03-06-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.